Institute for Clinical Diabetology, German Diabetes Centre, Leibniz Centre for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Department of Endocrinology and Diabetology, Medical Faculty, University Hospital Düsseldorf, Düsseldorf, Germany.
Handb Exp Pharmacol. 2022;274:269-307. doi: 10.1007/164_2021_576.
One of the microvascular complications of diabetes is diabetic kidney disease (DKD), often leading to end stage renal disease (ESRD) in which patients require costly dialysis or transplantation. The silent onset and irreversible progression of DKD are characterized by a steady decline of the estimated glomerular filtration rate, with or without concomitant albuminuria. The diabetic milieu allows the complex pathophysiology of DKD to enter a vicious cycle by inducing the synthesis of excessive amounts of reactive oxygen species (ROS) causing oxidative stress, inflammation, and fibrosis. As no cure is available, intensive research is required to develop novel treatments possibilities. This chapter provides an overview of the important pathomechanisms identified in diabetic kidney disease, the currently established therapies, as well as recently developed novel therapeutic strategies in DKD.
糖尿病的微血管并发症之一是糖尿病肾病(DKD),它常导致终末期肾病(ESRD),患者需要昂贵的透析或移植。DKD 的隐匿发病和不可逆转进展的特征是估算肾小球滤过率(eGFR)的稳步下降,伴有或不伴有白蛋白尿。糖尿病环境使 DKD 的复杂病理生理学进入恶性循环,导致过量的活性氧(ROS)合成,引起氧化应激、炎症和纤维化。由于目前尚无治愈方法,因此需要进行深入研究以开发新的治疗方法。本章概述了在糖尿病肾病中确定的重要发病机制、目前已建立的治疗方法,以及最近在 DKD 中开发的新治疗策略。